Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
51 hedge funds and large institutions have $10.3M invested in Aevi Genomic Medicine Inc in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 32 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
30% less funds holding
Funds holding: 73 → 51 (-22)
46% less capital invested
Capital invested by funds: $19.2M → $10.3M (-$8.93M)
66% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 32
84% less call options, than puts
Call options by funds: $13K | Put options by funds: $82K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.45M |
| 2 |
Goldman Sachs
New York
|
+$262K |
| 3 |
ECM
Element Capital Management
New York
|
+$180K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$162K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.99M |
| 2 |
BlackRock
New York
|
-$1.85M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$753K |
| 4 |
State Street
Boston,
Massachusetts
|
-$494K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$365K |
GNMX Hedge Fund Activity: Q2 2017 in Review
51 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2017, worth a combined $10.3M — down 46% from $19.2M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of GNMX and 11 opened new positions — a net loss of 21 holders — while 12 trimmed existing stakes and 15 added.
The largest buyer was Adage Capital Partners, adding an estimated $1.45M. The largest seller was Opaleye Management, exiting entirely with an estimated $1.99M sold.
- 51 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2017, down from 73 in Q1 2017.
- Funds reported $10.3M of Aevi Genomic Medicine Inc stock for Q2 2017, down 46% quarter-over-quarter.
- 11 funds opened new Aevi Genomic Medicine Inc positions in Q2 2017 and 32 closed out, a net change of -21 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q2 2017 was Adage Capital Partners, an estimated $1.45M added.
- The largest Aevi Genomic Medicine Inc seller in Q2 2017 was Opaleye Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q2 2017.